rfk jr glp-1 Jr. on coverage for medication, HHS cuts Can RFK Jr. Limit Ozempic

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

No matter how hard you try, they keep coming back

Packed with antioxidants and health-supporting compounds

GLP1 is a real, growing headwind for snacks GLP1 drugs are driving a seismic shift in how Americans eat - and the U.S

Explore the best Wegovy alternatives in 2026